Get all premium features to the best stock analysis tool

Finranks

Company

About us

Contact us

[email protected]

Follow us

Instagram
Telegram
LinkedIn

All rights reserved.

Privacy Policy Terms of Conditions

Home
Markets
Screener
News
About

TECH - Bio-Techne Corporation Latest News | Finranks

Home

TECH

B

Bio-Techne Corporation (TECH)

NMS – Real Time Price. Currency in USD

50.95

-1.75 (-3.32%)

At close: Mar 27, 2026, 4:00 PM EDT

50.95

0.00 (0.00%)

After-hours: Mar 27, 2026, 4:34 PM EDT

Summary
News
Chart
Financial
Dividends
Forecast
Ownership
Profile

Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite

Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite

New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. SPYRE™ Amplification Kits leverage sequential and enhanced layered amplification (seqLA™) technology enabling improved detection of low-abundance and challenging targets.

Should You Continue to Hold Bio-Techne Stock in Your Portfolio?

Should You Continue to Hold Bio-Techne Stock in Your Portfolio?

TECH expands via acquisitions and global growth, but biotech funding softness, U.S. academic spending pressure and competition cloud near-term outlook.

Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?

Is Bio-Techne Stock a Buy, Sell, or Hold After a Wealth Manager Dumps Its Entire Stake?

Hollow Brook Wealth Management sold its entire position in Bio-Techne -- 174,677 shares -- during the fourth quarter of 2025, for an estimated $10.7 million based on quarterly average pricing. The position was previously 2.3% of the fund's AUM as of the prior quarter.

Bio-Techne Corporation (TECH) Presents at Leerink Global Healthcare Conference 2026 Transcript

Bio-Techne Corporation (TECH) Presents at Leerink Global Healthcare Conference 2026 Transcript

Bio-Techne Corporation (TECH) Presents at Leerink Global Healthcare Conference 2026 Transcript

Why Is Techne (TECH) Down 15.1% Since Last Earnings Report?

Why Is Techne (TECH) Down 15.1% Since Last Earnings Report?

Techne (TECH) reported earnings 30 days ago. What's next for the stock?

Bio-Techne Corporation (TECH) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Bio-Techne Corporation (TECH) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Bio-Techne Corporation (TECH) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Bio-Techne to Present at Upcoming Investor Conferences

Bio-Techne to Present at Upcoming Investor Conferences

MINNEAPOLIS, Feb. 24, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that it will present at the following investor conferences: TD Cowen 46th Annual Health Care ConferenceMarch 3, 202611:10 AM EST Leerink Partners Global Healthcare ConferenceMarch 10, 20268:40 AM EDT A live webcast of the presentations can be accessed via the IR Calendar page of Bio-Techne's Investor Relations website at https://investors.bio-techne.com/ir-calendar. About Bio-Techne Bio-Techne Corporation (NASDAQ: TECH) is a global life sciences company providing innovative tools and bioactive reagents for the research and clinical diagnostic communities.

Videos

No Data

There is no data to display

Press releases

Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite

Bio-Techne Advances Spatial Biology with Modular Expansion of COMET™ Suite

New SPYRE™ Focus Panels (Stroma and Vessel) broaden modular panel options, enabling deeper targeted insights in spatial biology workflows. SPYRE™ Amplification Kits leverage sequential and enhanced layered amplification (seqLA™) technology enabling improved detection of low-abundance and challenging targets.

Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories

Bio-Techne's Ella Platform Achieves CE-IVD Marking Expanding Access to Rapid, Cartridge‑Based Immunoassays for European Clinical Laboratories

Ella benchtop instrument is now CE-IVD marked and available for sale in the EU Enables diagnostic assay developers to leverage a simplified platform that delivers speed and reproducible results with minimal hands-on time Provides confidence for use in clinical trials and in-house test development MINNEAPOLIS , Feb. 16, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH), a global provider of life science tools, reagents, and diagnostic products, today announced that the Ella benchtop immunoassay platform has received CE-IVD marking1 and is now available for sale in the European Union. This achievement brings Ella's hallmark ease of use, speed and reproducibility to clinical settings, helping laboratories streamline workflows and support timely decision-making.

Bio-Techne Announces Changes to its Leadership Team

Bio-Techne Announces Changes to its Leadership Team

Dr. Matt McManus to transition from his role as President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 Steve Crouse, Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment, effective March 1, 2026 MINNEAPOLIS, Feb. 11, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today announced that Dr. Matt McManus, President of Bio-Techne's Diagnostics and Spatial Biology Segment, will be transitioning from his role, effective March 1, 2026, and will remain with Bio-Techne for a period of time to support a smooth transition. Steve Crouse, currently Senior Vice President of Bio-Techne's Analytical Solutions Division, has been appointed President, Diagnostics and Spatial Biology Segment.

Bio-Techne Releases Second Quarter Fiscal 2026 Results

Bio-Techne Releases Second Quarter Fiscal 2026 Results

MINNEAPOLIS, Feb. 4, 2026 /PRNewswire/ -- Bio-Techne Corporation (NASDAQ: TECH) today reported its financial results for the second quarter ending December 31, 2025. Second Quarter FY2026 Highlights Second quarter revenue was $295.9 million with reported and organic growth flat to prior year.